Bulletin of Mathematical Biology

, Volume 67, Issue 1, pp 79–99

A mathematical model of Doxorubicin treatment efficacy for non-Hodgkin’s lymphoma: Investigation of the current protocol through theoretical modelling results

Authors

  • B. Ribba
    • Institute for Medical BioMathematics
    • Clinical Pharmacology Unit, Faculty of Medicine LaënnecUniversity of Lyon
  • K. Marron
    • Institute for Medical BioMathematics
    • Institute for Medical BioMathematics
  • T. Alarcón
    • Centre for Mathematical Biology, Mathematical InstituteUniversity of Oxford
    • Bioinformatics Unit, Department of Computer ScienceUniversity College London
  • P. K. Maini
    • Centre for Mathematical Biology, Mathematical InstituteUniversity of Oxford
Article

DOI: 10.1016/j.bulm.2004.06.007

Cite this article as:
Ribba, B., Marron, K., Agur, Z. et al. Bull. Math. Biol. (2005) 67: 79. doi:10.1016/j.bulm.2004.06.007

Abstract

Doxorubicin treatment outcomes for non-Hodgkin’s lymphomas (NHL) are mathematically modelled and computationally analyzed. The NHL model includes a tumor structure incorporating mature and immature vessels, vascular structural adaptation and NHL cell-cycle kinetics in addition to Doxorubicin pharmacokinetics (PK) and pharmacodynamics (PD). Simulations provide qualitative estimations of the effect of Doxorubicin on high-grade (HG), intermediate-grade (IG) and low-grade (LG) NHL. Simulation results imply that if the interval between successive drug applications is prolonged beyond a certain point, treatment will be inefficient due to effects caused by heterogeneous blood flow in the system.

Copyright information

© Society for Mathematical Biology 2005